OncoMatch/Clinical Trials/NCT07069335
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Is NCT07069335 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Olaparib 150 MG for ovarian cancer.
Treatment: Olaparib 150 MG — This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 deleterious or suspected deleterious germline or somatic mutation
deleterious or suspected deleterious germline or somatic BRCA-mutated
Required: BRCA2 deleterious or suspected deleterious germline or somatic mutation
deleterious or suspected deleterious germline or somatic BRCA-mutated
Disease stage
Metastatic disease required
advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
Demographics
Prior therapy
Must have received: PARP inhibitor (olaparib)
have been taking stable doses of olaparib for more than 3 months before screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07069335 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received PARP inhibitor.
Does this trial require BRCA1?
Yes, BRCA1 deleterious or suspected deleterious germline or somatic mutation is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 deleterious or suspected deleterious germline or somatic mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 74 years or younger and at least 19 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages